Pegfilgrastim - Amgen/Kyowa Hakko Kirin

Drug Profile

Pegfilgrastim - Amgen/Kyowa Hakko Kirin

Alternative Names: Filgrastim SD01; G-Lasta; KRN125; Neulasta; Neulasta Onpro® Kit; Neulastim; PEG filgrastim; PEG G-CSF; PEG-rmetHuG-CSF; Pegylated filgrastim; R 1471; r-metHuG-CSF-SD-01; SD-01; SD/01

Latest Information Update: 14 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Kyowa Hakko Kirin
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neutropenia; Radiation injuries
  • Phase II Breast cancer

Most Recent Events

  • 01 Jul 2018 Phase-II clinical trials in Breast cancer (Neoadjuvant therapy, Combination therapy, Second-line therapy or greater) in France (SC) (NCT03571633)
  • 28 Feb 2018 The Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion recommending a label variation for Neulasta to include the Neulasta Onpro® Kit
  • 01 Nov 2015 Launched for Radiation injuries in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top